Mydecine Files Full Patent Application Covering MYCO-006 Family of Novel Short-Acting MDMA Analogs Post published:July 20, 2022 Post category:Press Release
U.S. FDA Clears MYCO-001 for Multi-Site Government Funded Trial in Smoking Cessation Post published:June 17, 2022 Post category:Press Release
Mydecine Reports Financial Results for the Fiscal Year 2021 and Provides a Business Update Post published:April 1, 2022 Post category:Press Release
Mydecine Innovations Group Announces Closing of First Tranche Under Share Subscription Agreement Post published:March 31, 2022 Post category:Press Release
Mydecine Receives Conditional IRB Approval for Phase 2b Smoking Cessation Study Post published:March 24, 2022 Post category:Press Release
Mydecine Reports Positive Pre-IND Meeting With FDA For MYCO-001 Smoking Cessation Study Post published:March 1, 2022 Post category:Press Release
Mydecine Announces MYCO-005 Family of Improved Safety Microdose Novel Molecules Post published:February 16, 2022 Post category:Press Release
Mydecine’s Exclusive Dealer Identified as Licensed Psilocybin and MDMA Supplier in Canada Post published:February 8, 2022 Post category:Press Release
Mydecine Welcomes Dr. Victoria Hale as Newest Independent Board Member Post published:February 3, 2022 Post category:Press Release